Siamak Daneshmand

23.0k total citations · 2 hit papers
471 papers, 10.9k citations indexed

About

Siamak Daneshmand is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Urology. According to data from OpenAlex, Siamak Daneshmand has authored 471 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 426 papers in Surgery, 124 papers in Pulmonary and Respiratory Medicine and 110 papers in Urology. Recurrent topics in Siamak Daneshmand's work include Bladder and Urothelial Cancer Treatments (309 papers), Urinary and Genital Oncology Studies (188 papers) and Urological Disorders and Treatments (96 papers). Siamak Daneshmand is often cited by papers focused on Bladder and Urothelial Cancer Treatments (309 papers), Urinary and Genital Oncology Studies (188 papers) and Urological Disorders and Treatments (96 papers). Siamak Daneshmand collaborates with scholars based in United States, Canada and Germany. Siamak Daneshmand's co-authors include Gus Miranda, Eila C. Skinner, Hooman Djaladat, Marcus L. Quek, Hamed Ahmadi, Jie Cai, Donald G. Skinner, Anne Schuckman, Stephen A. Boorjian and John P. Stein and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Siamak Daneshmand

429 papers receiving 10.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

2016 937 citations Stephen A. Boorjian, Siamak Daneshmand et al. profile →
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes

2015 467 citations Siamak Daneshmand, Yair Lotan et al. European Urology profile →

Peers

Countries citing papers authored by Siamak Daneshmand

Since Specialization

Citations

This map shows the geographic impact of Siamak Daneshmand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siamak Daneshmand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siamak Daneshmand more than expected).

Fields of papers citing papers by Siamak Daneshmand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siamak Daneshmand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siamak Daneshmand. The network helps show where Siamak Daneshmand may publish in the future.

Co-authorship network of co-authors of Siamak Daneshmand

This figure shows the co-authorship network connecting the top 25 collaborators of Siamak Daneshmand. A scholar is included among the top collaborators of Siamak Daneshmand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siamak Daneshmand. Siamak Daneshmand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy 2025 ·European Urology Open Science ·Joep J. de Jong, (unknown), Siamak Daneshmand, Robert S. Svatek, Vikram M. Narayan, Elai Davicioni, Shreyas Joshi, (unknown), Roger Li, Brant A. Inman, Paras Shah, (unknown), Jonathan L. Wright, Ewan A. Gibb, Yair Lotan	1
2	Impact of neighborhood deprivation on bladder cancer outcomes: A regional analysis 2025 ·Bladder Cancer ·(unknown), Chirag Doshi, Mazyar Zahir, (unknown), (unknown), (unknown), (unknown), Leilei Xia, Gus Miranda, Jie Cai, Hooman Djaladat, Anne Schuckman, Siamak Daneshmand	0
3	Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial 2024 ·European Urology ·Elizabeth R. Plimack, Catherine M. Tangen, Melissa Plets, (unknown), Joanne Xiu, Chadi Nabhan, Eric A. Ross, (unknown), Woonyoung Choi, (unknown), (unknown), (unknown), M. Scott Lucia, Siamak Daneshmand, Dan Theodorescu, Amir Goldkorn, Seth P. Lerner, Thomas W. Flaig, David J. McConkey	7
4	MARKER LESION STUDY OF ORAL ERDAFITINIB IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE–INVASIVE BLADDER CANCER WITH FGFR3/2 ALTERATIONS IN THOR-2: UPDATED COHORT 3 RESULTS 2024 ·Urologic Oncology Seminars and Original Investigations ·Siamak Daneshmand, Renata Zaucha, Nikhil Vasdev, Benjamin A. Gartrell, Yair Lotan, Syed A. Hussain, Eugene K. Lee, Giuseppe Procopio, (unknown), G. Pignot, Debasish Sundi, (unknown), (unknown), Vahid Naini, Spyros Triantos, Mahadi Baig, Jodi K. Maranchie	1
5	Blood-based liquid biopsy: A promising noninvasive test in diagnosis, surveillance, and prognosis of patients with upper tract urothelial carcinoma 2024 ·Urologic Oncology Seminars and Original Investigations ·Alireza Ghoreifi, Stephanie N. Shishido, (unknown), (unknown), Amy H. Huang, Anne Schuckman, Monish Aron, Mihir Desai, Siamak Daneshmand, Inderbir S. Gill, Peter Kühn, Hooman Djaladat, (unknown)	1
6	Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non–muscle-invasive Bladder Cancer 2024 ·European Urology Oncology ·Félix Guerrero‐Ramos, Joost L. Boormans, Siamak Daneshmand, Paolo Gontero, Ashish M. Kamat, Morgan Rouprêt, Antoni Vilaseca, Shahrokh F. Shariat	9
7	Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma. 2024 ·Journal of Clinical Oncology ·Axel Heidenreich, Siamak Daneshmand, (unknown), (unknown), Pia Paffenholz, Alireza Ghoreifi, (unknown), Marcus Hentrich, (unknown), Peter Albers, Clint Cary, Axel Gerdtsson, Anders Kjellman, Helene F. S. Negaard	0
8	Abstract LB327: DNA methylation biomarkers for early bladder cancer detection and treatment response monitoring 2024 ·Cancer Research ·(unknown), Siamak Daneshmand, (unknown), (unknown), (unknown), (unknown), Alireza Ghoreifi, Michael Basin, (unknown), Yap Ching Chew, Jeffrey Bhasin, (unknown), (unknown), Hooman Djaladat, (unknown), (unknown), Gangning Liang	0
9	A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy 2024 ·British Journal of Urology ·Joep J. de Jong, (unknown), Siamak Daneshmand, Robert S. Svatek, Vikram M. Narayan, Ewan A. Gibb, Elai Davicioni, Shreyas Joshi, (unknown), Roger Li, Brant A. Inman, Paras Shah, (unknown), Jonathan L. Wright, Yair Lotan	1
10	Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma 2023 ·European Urology ·Thomas Powles, Zoe J. Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Himanshu Sethi, Alexey Aleshin, Yi Shi, Nicole N. Davarpanah, Corey Carter, Joaquim Bellmunt, Sanjeev Mariathasan	61
11	Commentary on Novitas LCD 2023 ·Bladder Cancer ·Yair Lotan, Daniel A. Barocas, Sam S. Chang, Siamak Daneshmand, Badrinath R. Konety, Joshua J. Meeks, Sima P. Porten, Jay D. Raman, Charles J. Rosser, Kristen R. Scarpato, Wade J. Sexton, John P. Sfakianos, Neal D. Shore, Robert S. Svatek	1
12	A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695) 2021 ·Clinical Cancer Research ·Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, Ian M. Thompson	58
13	SEMS trial: Result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma. 2021 ·Journal of Clinical Oncology ·Siamak Daneshmand, Clint Cary, Timothy A. Masterson, Lawrence Einhorn, Stephen A. Boorjian, Christian Kollmannsberger, Anne Schuckman, (unknown), Peter C. Black, Aditya Bagrodia, Eila C. Skinner, Mehrdad Alemozaffar, Timothy C. Brand, Scott E. Eggener, Phillip M. Pierorazio, Kelly Stratton, Lucia Nappi, Craig R. Nichols, Brian Hu	21
14	Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples 2021 ·Clinical Epigenetics ·(unknown), Yap Ching Chew, (unknown), (unknown), (unknown), Xi-Yu Jia, Wei Guo, Saum Ghodoussipour, Siamak Daneshmand, Hamed Ahmadi, (unknown), Jeffrey Bhasin, (unknown), Yvonne Tsai, Yoshitomo Chihara, Gangning Liang	30
15	Reporting radical cystectomy outcomes following implementation of Enhanced Recovery after Surgery (ERAS) protocols: A systematic review and individual patient data meta-analysis 2020 ·European Urology Open Science ·(unknown), Marcus Cumberbatch, Ashish M. Kamat, (unknown), John McGrath, Hooman Djaladat, Justin Collins, Ibrahim Jubber, Vignesh T. Packiam, Gary D. Steinberg, (unknown), Wassim Kassouf, Peter C. Black, Yannick Cerantola, James W.F. Catto, Siamak Daneshmand	15
16	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature 2020 ·Clinical Genitourinary Cancer ·Leslie K. Ballas, (unknown), Siamak Daneshmand, Anne Schuckman, Hooman Djaladat, Monish Aron, Anishka D'souza, David I. Quinn, Tanya B. Dorff	0
17	Optimizing Diagnosis of Urothelial Bladder Cancer with Blue Light Cystoscopy via Recognition of False-Positive Lesions 2018 ·Videourology ·Soroush Bazargani, Hooman Djaladat, Anne Schuckman, (unknown), Siamak Daneshmand	2
18	Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort 2018 ·Urologic Oncology Seminars and Original Investigations ·Giancarlo Marra, Paolo Gontero, (unknown), Claudia Filippini, Umberto Capitanio, Francesco Montorsi, Siamak Daneshmand, William C. Huang, Estefanía Linares, Juan Ignacio Martínez‐Salamanca, James M. McKiernan, Richard Zigeuner, John A. Libertino	5
19	A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence 2014 ·Clinical Cancer Research ·Sheng‐Fang Su, Andre Luis Abreu, Yoshitomo Chihara, Yvonne Tsai, Claudia Andreu‐Vieyra, Siamak Daneshmand, Eila C. Skinner, Peter A. Jones, Kimberly D. Siegmund, Gangning Liang	75
20	New molecular markers for bladder cancer detection 2004 ·Current Opinion in Urology ·Marcus L. Quek, Kristin M. Sanderson, Siamak Daneshmand, John P. Stein	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact